CTXRNasdaqPharmaceutical PreparationsUS GAAP · USD

Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company focused on developing and commercializing first-in-class critical care and oncology products. In December 2025, it became a commercial-stage company through the launch of LYMPHIR by its majority-owned subsidiary Citius Oncology, while still advancing late-stage assets such as Mino-Lok, Halo-Lido, and NoveCite.

Kysy yhtiöstä
Liikevoitto (EBIT)−38,5milj. USD
+8,3 %v/v
Nettotulos−39,7milj. USD
−0,8 %v/v
Vapaa kassavirta−26,6milj. USD
+5,8 %v/v

Tilikausi 2025 · muutos edellisvuodesta

Kehitys 2020–2025

−50−40−30−20−10010milj. USD2020: 0,09 milj. USD2020: EBIT −18 milj. USD20202021: 0,09 milj. USD2021: EBIT −24 milj. USD20212022: 0,09 milj. USD2022: EBIT −33 milj. USD20222023: EBIT −37 milj. USD20232024: EBIT −42 milj. USD20242025: EBIT −39 milj. USD2025−39
LiikevaihtoLiikevoitto (EBIT)

Liiketoiminta

Osuus liikevaihdosta
Commercial oncology product70 %

LYMPHIR is the company's commercial immunotherapy for persistent or recurrent CTCL.

Late-stage critical care anti-infective15 %

Mino-Lok is an antibiotic lock solution intended to salvage infected catheters.

Topical prescription product5 %

Halo-Lido is a corticosteroid-lidocaine formulation for hemorrhoid symptom relief.

Cell therapy development asset5 %

NoveCite is a mesenchymal stem cell program for acute respiratory distress syndrome.

Business development and commercialization5 %

This includes in-licensing, development, and third-party commercialization support.

Asiakkaat

The company sells into narrow specialty physician and hospital channels, especially in oncology and critical care. Its target buyers include physicians, hospitals, and distributors that support treatment of rare or hard-to-treat conditions, with payer acceptance important because the products are positioned as cost-effective therapies for unmet needs.

Specialty oncology physicians

Buy or prescribe LYMPHIR for CTCL patients because it addresses a rare oncology indication with limited options.

Hospital and critical care clinicians

Would use Mino-Lok in catheter infection settings to salvage lines and avoid catheter replacement.

Payers and pharmacy benefit stakeholders

Influence access and reimbursement for specialty products by evaluating clinical value and cost-effectiveness.

Commercial distribution partners

Cardinal Health, Cencora, McKesson, and EVERSANA support product distribution and launch execution.

Patients with hemorrhoids or ARDS-related needs

End users for Halo-Lido and NoveCite, though these programs remain development-stage or pre-commercial.

Strategia

The company is focused on building value through a small number of specialty products that can be commercialized with a narrow physician audience and limited sales infrastructure. Near term, the priority is to scale LYMPHIR through Citius Oncology while preserving optionality for Mino-Lok, Halo-Lido, and NoveCite through partnerships, licensing, or future commercialization.

Commercialize LYMPHIRLyhyt aikaväli

It is the first approved and launched product and the main near-term revenue driver.

Maintain a capital-light operating modelLyhyt aikaväli

The company has limited cash and needs to preserve resources while advancing multiple programs.

Advance late-stage pipeline assetsKeskipitkä aikaväli

Mino-Lok, Halo-Lido, and NoveCite provide future optionality beyond LYMPHIR.

Evaluate strategic alternativesLyhyt aikaväli

Management is seeking ways to maximize shareholder value and fund future operations.

Maantiede

Citius Pharmaceuticals is headquartered in Cranford, New Jersey and operates primarily from the United States. Its commercial and development footprint is U.S.-centric, with manufacturing and launch activities outsourced to third-party partners and supply agreements for LYMPHIR tied to compliant facilities.

Riskit

Citius remains highly dependent on successful commercialization of LYMPHIR and on external financing, with a history of operating losses and negative working capital. The business also faces typical biotech risks around regulatory approval, market adoption, third-party manufacturing, and dependence on partners for sales, distribution, and supply.

Järjestetty vakavuuden mukaan
MatalaKohtalainenKorkeaMatalaKohtalainenKorkeaVaikutus →Todennäköisyys →Insufficient capital to fund operations1Commercial execution risk for LYMPHIR2Regulatory and compliance risk3Reliance on third-party manufacturers4Partner dependence5Merger and spinout-related uncertainty6
Vaikutus on riskin vakavuus ja todennäköisyys sen toteutumisen todennäköisyys lähivuosina, molemmat arvioitu yhtiön raporttien perusteella. Numerot vastaavat listaa.
  1. Insufficient capital to fund operationsVaikutus: KriittinenTodennäköisyys: Korkea

    The company has a history of losses, negative working capital, and limited cash, so it must raise external capital or generate product revenue.

    Kohdistuu: Corporate liquidity and commercialization plans

  2. Commercial execution risk for LYMPHIRVaikutus: KorkeaTodennäköisyys: Korkea

    Revenue depends on successful launch, payer access, and physician adoption in a narrow oncology market.

    Kohdistuu: LYMPHIR sales and market acceptance

  3. Regulatory and compliance riskVaikutus: KorkeaTodennäköisyys: Korkea

    Drug development and commercialization require FDA and other regulatory approvals and ongoing compliance.

    KohdistuuProduct approvalsLabelingMarket access
  4. Reliance on third-party manufacturersVaikutus: KorkeaTodennäköisyys: Kohtalainen

    The company depends on a limited number of cGMP-compliant facilities for commercial supply.

    Kohdistuu: LYMPHIR and future product supply

  5. Partner dependenceVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    Sales, marketing, and distribution are outsourced, so execution depends on third parties.

    Kohdistuu: Commercial launch and product reach

  6. Merger and spinout-related uncertaintyVaikutus: KeskitasoTodennäköisyys: Kohtalainen

    The separation of LYMPHIR into Citius Oncology may not deliver the expected value creation or market benefits.

    Kohdistuu: Corporate structure and shareholder value

Kirjanpito

Harkinnanvaraiset erät
In-process research and development valuation

The company carries significant acquired intangible assets for Mino-Lok and LYMPHIR that depend on future commercialization success.

Vaikutus: Amortization begins only when revenue generation starts; impairment risk remains if prospects weaken.

Goodwill impairment testing

Goodwill from the Leonard-Meron acquisition must be tested annually and when events indicate impairment.

Vaikutus: A write-down would reduce earnings and reported equity.

Contingent milestone liabilities

The company owes approval-related milestone amounts to Dr. Reddy's and has made payments to Eisai.

Vaikutus: These obligations affect cash flow and balance sheet liabilities.

Stock-based compensation

Equity awards are used to compensate employees and executives in a cash-constrained biotech model.

Vaikutus: Raises operating expenses and can dilute shareholders.

Supply and purchase commitments

Commercial supply agreements for LYMPHIR include minimum purchase commitments.

Vaikutus: Creates future cash obligations and working capital pressure.

Samankaltaisia listattuja yhtiöitä

Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.

Citius Oncology, Inc

CTOR · Pharmaceutical Preparations

Liminatus Pharma, Inc.

LIMNW · Biological Products, (No Diagnostic Substances)

CytomX Therapeutics, Inc.

CTMX · Pharmaceutical Preparations

Coherus Oncology, Inc.

CHRS · Biological Products, (No Diagnostic Substances)

Xilio Therapeutics, Inc.

XLO · Pharmaceutical Preparations

LadRx Corp

Biological Products, (No Diagnostic Substances)

Päivitetty: 24.9.2026